Inventerra receives US Phase 1 clinical trial approval for oral contrast agent for pancreaticobiliary imaging
Predicted impact: Low
US Phase 1 trial approval for an early-stage agent; no revenue and small market value.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.